AC Immune (ACIU) - What Are Analysts Saying About This Stock?

AC Immune logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts have a “Moderate Buy” consensus on AC Immune, with two Buy, one Strong Buy, one Hold and one Sell rating; the average 12-month price target is $7.50.
  • Recent analyst views are mixed: HC Wainwright initiated coverage with a Strong Buy, while Zacks Research downgraded the stock to Hold; BTIG maintained Buy with an $8 target.
  • AC Immune reported a quarterly loss of $0.16 per share, beating estimates of $0.18, and revenue of $3.88 million versus $1.62 million expected. Institutional investors own about 51% of the company.
  • MarketBeat previews the top five stocks to own by December 1st.

Shares of AC Immune (NASDAQ:ACIU - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $7.50.

Several analysts have recently issued reports on ACIU shares. HC Wainwright initiated coverage on shares of AC Immune in a research note on Thursday, November 5th. They issued a "strong-buy" rating for the company. Zacks Research lowered AC Immune from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 28th. BTIG Research reissued a "buy" rating and set a $8.00 price objective on shares of AC Immune in a research note on Wednesday, September 23rd. Finally, Weiss Ratings raised shares of AC Immune from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, November 3rd.

Read Our Latest Report on ACIU

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. AXQ Capital LP purchased a new stake in shares of AC Immune in the 2nd quarter valued at $25,000. Marshall Wace LLP purchased a new position in AC Immune in the 3rd quarter worth approximately $48,000. Arrowstreet Capital Limited Partnership lifted its position in AC Immune by 8.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company's stock valued at $1,116,000 after purchasing an additional 30,035 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in AC Immune by 82.8% in the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company's stock valued at $1,071,000 after purchasing an additional 176,701 shares during the last quarter. 51.36% of the stock is currently owned by institutional investors.

AC Immune Trading Up 1.7%

NASDAQ:ACIU opened at $2.13 on Friday. The stock has a market cap of $217.28 million, a P/E ratio of -4.27 and a beta of 1.64. The stock's 50-day moving average is $2.44 and its 200-day moving average is $2.64. AC Immune has a 1-year low of $2.00 and a 1-year high of $3.90.

AC Immune (NASDAQ:ACIU - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02. The firm had revenue of $3.88 million for the quarter, compared to the consensus estimate of $1.62 million. AC Immune had a negative net margin of 181.38% and a negative return on equity of 105.25%. As a group, equities analysts forecast that AC Immune will post -0.54 EPS for the current year.

About AC Immune

(Get Free Report)

AC Immune SA is a Swiss biopharmaceutical company focused on developing precision medicines and diagnostic products for neurodegenerative diseases. Its research programs address conditions including Alzheimer's and Parkinson's diseases, as well as other neurological disorders. The company's pipeline includes immunotherapies and small-molecule drug candidates designed to target proteins associated with neurodegeneration. AC Immune also develops diagnostic approaches and uses proprietary technology platforms, including SupraAntigen and Morphomer, to identify and advance potential treatments.

Further Reading

Analyst Recommendations for AC Immune (NASDAQ:ACIU)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AC Immune Right Now?

Before you consider AC Immune, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AC Immune wasn't on the list.

While AC Immune currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines